Cargando…
Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy
Quantitative understanding about the dynamics of drug–target interactions in biological systems is essential, especially in rare disease programs with small patient populations. Follistatin, by antagonism of myostatin and activin, which are negative regulators of skeletal muscle and inflammatory res...
Autores principales: | Nguyen, Hoa Q., Iskenderian, Andrea, Ehmann, David, Jasper, Paul, Zhang, Zhiwei, Rong, Haojing, Welty, Devin, Narayanan, Rangaraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306616/ https://www.ncbi.nlm.nih.gov/pubmed/32419339 http://dx.doi.org/10.1002/psp4.12518 |
Ejemplares similares
-
Current Pharmacological Strategies for Duchenne Muscular Dystrophy
por: Yao, Shanshan, et al.
Publicado: (2021) -
Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017) -
Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012) -
Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021) -
Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2015)